Skip to main content
OpenTrials
Completed

NCT Number: NCT03317041

Capacitive-resistive Electric Transfer Therapy for Recovery From Running Fatigue

Reducing fatigue and improving the recovery capabilities of runners has gained more interest over the last years. Recently, capacitive-resistive electric transfer (Tecar) therapy is commonly used by physical therapists to help athletes recover from muscle fatigue. However, empiric evidence supporting the benefits of Tecar to recovery is lacking. This study investigated the effects of a Tecar treatment performed shortly after an exhausting training session on both physiological and biomechanical parameters of running.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Running Fatigue Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

About this study

In this randomized controlled crossover trial all subjects will perform two test protocols separated by 2 weeks. Each protocol will comprise one exhausting training session (20-min warm-up consisted of 15-min of continuous self-paced running followed by 5-min of fast-finish progression runs increasing speeds (from approximately 60% to 80% of maximal heart rate, participant controlled), 10 x 500 m sprints at 90% of maximal heart rate with a 2-min rest period between bouts and a recovery phase consisting of 10-min of slow jogging). Twenty-four hours after this exhausting training, subjects will perform an incremental running test on a treadmill (Pre-intervention test) where subjects will start at 10 km/h for 6 min after which speed will be increased by 2 km/h every 6 min until a 16 km/h trial is completed. One hour after this test, in one protocol subjects will receive Tecar therapy (Tecar treatment group); in the other group (Control group) participants will rest passively in a sitting position for 30-min period. To evaluate the relevance of the changes induced by Tecar therapy/passive recovery, subjects will repeat the treadmill test 48 hours after the first test in both groups (72 hours after the exhaustive training).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Recreationally active (current participation in races and a 10-km race time <34.5-min)

Exclusion criteria

  • Suffered from any injury within the preceding 4 months.

Treatment and study plan

Capacitive-resistive electric transfer (Tecar) therapy

Other

The Tecar treatment group will receive 45 minutes of Tecar therapy treatment. Subjects will lay down with the face down and two metallic plaques situated under each quadriceps muscle all over all the treatment. The treatment will start with the automatic capacitive energy transfer for 10-min where the capacitive plaque is situated on the sole of each foot with an elastic band. After that, the capacitive plaque will be pulled out. Then, the resistive electrode will be moved longitudinally through different muscles with massage lotion during 15-min per each lower extremity. The treatment will conclude with the automatic capacitive energy transfer for 10-min and the capacitive plaque situated on the sole of each foot with an elastic band.

Primary outcomes

  1. CHANGE FROM BASELINE OXYGEN UPTAKE AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    Oxygen uptake (mL kg-1 min-1) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Oxygen uptake will be recorded using a gas analyzer system (Esgostik Geratherm, Geschwenda, Germany).

  2. CHANGE FROM BASELINE RESPIRATORY EXCHANGE RATIO AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    Respiratory exchange ratio (ratio between the amount of carbon dioxide (CO2) produced in metabolism and oxygen (O2)) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Respiratory exchange ratio will be recorded using a gas analyzer system (Esgostik Geratherm, Geschwenda, Germany).

  3. CHANGE FROM BASELINE VENTILATION AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    Ventilation (L• min-1) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Ventilatory output will be recorded using a gas analyzer system (Esgostik Geratherm, Geschwenda, Germany).

  4. CHANGE FROM BASELINE HEART RATE AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    Heart rate (beat • min-1) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Heart rate will be recorded by a heart monitor (Polar RS800, Kempele, Finland).

  5. CHANGE FROM BASELINE BLOOD LACTATE CONCENTRATION AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    • Blood lactate concentration (mmol •L-1) will be assessed in an incremental running test on a treadmill (HP Cosmos pulsar, Nussdorf-Traunstein, Germany). Capillary blood samples will be obtained in each test from the earlobe for the determination of blood lactate concentration by a portable lactate analyzer (Lactate, Arkray, KDK Corporation, Kyoto, Japan).

  6. CHANGE FROM BASELINE STRIDE LENGTH AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    Stride length (cm), defined as the length the treadmill belt moves from toe-off to initial ground contact in successive steps, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.

  7. CHANGE FROM BASELINE STRIDE FREQUENCY AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    Stride frequency, defined as the number of ground contact events per minute, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.

  8. CHANGE FROM BASELINE STRIDE ANGLE AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    Stride angle (º), defined as the angle of the parable tangent derived from the theoretical arc traced by a foot during a stride and the ground, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.

  9. CHANGE FROM BASELINE GROUND CONTACT TIME AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    Ground contact time (s), defined as the time from when the foot contacts the ground to when the toes left the ground and was determined by the disruption of the infrared gates, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.

  10. CHANGE FROM BASELINE SWING TIME AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    The swing time (s) corresponds to the time from foot flat to initial take-off. Swing time will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.

  11. CHANGE FROM BASELINE CONTACT PHASE AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    Contact phase (%), defined as the percentage of the ground contact time at which the different sub-phases of stance phase occur, will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.

  12. CHANGE FROM BASELINE SUPPORT PHASE AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    The support sub-phase (%) corresponds to the time from initial ground contact to foot flat.

    Support phase will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.

  13. CHANGE FROM BASELINE PUSH-OFF PHASE AT 48 HOURS AFTER THE TREATMENT.

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session) and at 48 hours after the treatment.

    The push-off phase (%) corresponds to the time from initial take-off to toe-off.

    Push-off phase will be measured using an optical measurement system (Optojump-next, Microgate, Bolzano, Italy) placed at the treadmill belt level.

Secondary outcomes

  1. Body height (cm)

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session).

    Body height will be measured using a stadiometer (Año Sayol, Barcelona, Spain) following the guidelines outlined by the International Society for the Advancement of Kinanthropometry.

  2. Body weight (kg)

    Time frame: Participants will be assessed at baseline (24 hours after an exhaustive training session).

    Body weight will be measured using a balance (Año Sayol, Barcelona, Spain) following the guidelines outlined by the International Society for the Advancement of Kinanthropometry.

Sponsors and collaborators

Lead sponsor

University of the Basque Country (UPV/EHU)

Other

Registry information

Official study title

Effects of a Capacitive-resistive Electric Transfer Therapy Exposure on Physiological and Biomechanical Parameters in Recreational Runners: a Randomized Controlled Crossover Trial

Acronym: UPV/EHU

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Oct 23, 2017
Registry last updated
Oct 23, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.